全体基調セッションの講演者

4月30日 (月) 、16:00 - 17:40

タンパク質バイオ医薬品エンジニアリングの課題と可能性
K. Dane Wittrup, PhD, C.P. Dubbs Professor, Chemical Engineering and Biological Engineering; Associate Director, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology (MIT)

K. Dane Wittrup, PhD
Professor K. Dane Wittrup is the Carbon P. Dubbs Professor of Chemical Engineering and Biological Engineering at the Massachusetts Institute of Technology, and the Associate Director of the Koch Institute for Integrative Cancer Research. From 1989-1999 he was Assistant Professor, Associate Professor, and then J. W. Westwater Professor of Chemical Engineering, Bioengineering, and Biophysics at the University of Illinois in Champaign/Urbana. Prof. Wittrup received a B.S. in Chemical Engineering Summa cum Laude in 1984 from the University of New Mexico, and a Ph.D. in Chemical Engineering from the California Institute of Technology in 1988 under the thesis direction of Prof. James Bailey. Following a year of postdoctoral research at Amgen (Thousand Oaks, CA), Dr. Wittrup joined the faculty at the University of Illinois. Wittrup's research program is focused on protein engineering of biopharmaceutical proteins by directed evolution. Areas of interest include: pretargeted radioimmunotherapy; biological response modification of EGFR; and immunotherapy of cancer via engineered cytokines and vaccines.

Prof. Wittrup has received the following awards and honors recognizing his scholarship: the A. McLaren White Award, for First Prize in the National American Institute of Chemical Engineers Student Design Contest (1984); the Presidential Young Investigator Award of the National Science Foundation (1990-1995); the Allan P. Colburn Award of the American Institute of Chemical Engineers, for excellence in publications for an individual under the age of 35 (1998); the University of New Mexico College of Engineering Distinguished Young Alumnus Award (2000); the Dow Chemical Company Teaching Award(1989); the UIUC School of Chemical Sciences Award for Excellence in Teaching (1993); the UIUC College of Engineering Anderson Award for Undergraduate Advising (1991, 1994); the J.R. Mares Professorship (1999- 2007); the C.P. Dubbs Professorship (2007-); induction as a Fellow of the American Institute of Medical and Biological Engineers (1999); induction as Fellow, American Association for the Advancement of Science (2011); and Member, National Academy of Engineering (2012). Prof. Wittrup has mentored the following Ph.D. students and postdoctoral fellows who are now faculty members: Jennifer Cochran (Bioengineering, Stanford University); Ben Hackel (Chemical Engineering, University of Minnesota); Anne Robinson (Chemical Engineering, Tulane University); David Colby (Chemical Engineering, University of Delaware); Eric Boder (Chemical Engineering, University of Tennessee); Eric Shusta (Chemical Engineering, University of Wisconsin, Madison); Jennifer van Antwerp (Chemical Engineering, Calvin College); Balaji Rao (Chemical Engineering, North Carolina State University); Yong-Sung Kim (Biotechnology, Ajou University, Korea); Mark Olsen (Biochemistry, Texas A & M, Amarillo). In 2007, Prof. Wittrup co-founded Adimab, Inc. with Tillman Gerngross of Dartmouth University, and serves as CSO. In 2009, he co-founded Eleven Biotherapeutics, and serves on the Scientific Advisory Board.


2018年の若手研究者基調講演

次世代のがん免疫療法:骨髄免疫チェックポイントの標的化

Kipp Weiskopf, MD, PhD, Resident Physician, Internal Medicine, Brigham and Women's Hospital

Immune cells of the myeloid lineage hold tremendous potential as effectors of cancer immunotherapy. The CD47/SIRPα axis is a key molecular pathway that governs the interaction between myeloid cells and tumors. Therapies that target the interaction are effective across multiple preclinical models of cancer and are now under investigation in clinical trials. Further studies have revealed additional regulators of myeloid cell activation that can be exploited as myeloid immune checkpoints.



Kipp_WeiskopfKipp Weiskopf, MD, PhD, Resident Physician, Internal Medicine, Brigham and Women's Hospital

Kipp Weiskopf, M.D., Ph.D., is a resident physician in Internal Medicine at Brigham and Women's Hospital in Boston, MA. He completed his training in the Medical Scientist Training Program at Stanford University. His research focuses on the development of novel cancer immunotherapies, particularly those that activate innate immune cells to attack cancer. In the laboratory of Irving Weissman, M.D., he studied the interaction between CD47 and SIRPα, which acts as a myeloid-specific immune checkpoint. He developed novel therapies that disrupt the CD47-SIRPa interaction and stimulate macrophage phagocytosis of cancer cells. He has over 10 patent applications related to this work and was a winner of the 2013 Collegiate Inventors Competition at the US Patent and Trademark Office. He is a co-Founder of Alexo Therapeutics, a biotech company formed to develop these therapeutics. He has also been the recipient of a Winston Churchill Scholarship, an NCI Ruth L. Kirschstein NRSA Fellowship, the Harold M. Weintraub Graduate Student Award from the Fred Hutchinson Cancer Research Center, and the Joanna M. Nicolay Melanoma Foundation Research Scholar Award.

Choose your language
Traditional Chinese
Simplified Chinese
Korean
English

更新通知サービス
カタログ (PDF)
ダウンロード
カタログ(PDF)